ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1164

Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Abstract Number: 1165

Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Abstract Number: 1166

Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Abstract Number: 1167

Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Abstract Number: 1168

Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
Abstract Number: 1169

All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China
Abstract Number: 1170

Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Abstract Number: 1171

Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1172

Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Abstract Number: 1173

Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Abstract Number: 1174

Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review
Abstract Number: 1175

Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Abstract Number: 1176

Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Abstract Number: 1177

Anti-HMGCR Autoantibody Levels in the Follow-up of Statin-induced Immune-mediated Necrotizing Myopathy: Multicentric Study of 24 Patients
Abstract Number: 1178

Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].